ArticleTranslational lung cancer research2016
Second-line therapy for small cell lung cancer: exploring the potential role of circulating tumor cells.
Article in Translational lung cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer.Frontiers in immunology · 2025Review
- Circulating tumor cell-derived preclinical models: current status and future perspectives.Cell death & disease · 2023Review
- Significance of circulating tumor cells in lung cancer: a narrative review.Translational lung cancer research · 2023Review
- Changes of protein expression during tumorosphere formation of small cell lung cancer circulating tumor cells.Oncology research · 2023Article
- Review
- Review
- Toward a New Era for the Management of Circulating Tumor Cells.Advances in experimental medicine and biology · 2021Review
- Review
- Are there any theranostic biomarkers in small cell lung carcinoma?Journal of thoracic disease · 2019Review
- Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration.Oncotarget · 2017Review
- Circulating tumor cell interactions with macrophages: implications for biology and treatment.Translational lung cancer research · 2017Review
- Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance.Scientific reports · 2017Article
- Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.Cell adhesion & migration · 2016Article
- Liquid biopsy and NSCLC.Lung cancer management · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmall cell lung cancer (SCLC) is an aggressive and invasive variant of lung tumors. SCLC, especially in advanced stages, is distinguished by extremely high numbers of circulating tumor cells (CTCs) in comparison to other malignancies. CTCs are operative in tumor spread and are currently enumerated to assess prognosis and response to cytotoxic therapy. Chemosensitivity of SCLC CTCs compared to primary tumors and metastases is not known.
methodsEstablishment of two SCLC CTC cell lines, namely BHGc7 and BHGc10, allowed the in vitro characterization of their chemosensitivity to the second-line chemotherapeutics topotecan and epirubicin in comparison to a range of SCLC cell lines.
resultsThe SCLC CTC cell lines exhibited an approximately 7- and 12-fold increased chemosensitivity to epirubicin compared to topotecan, respectively, in in vitro cytotoxicity assays. In comparison to a panel of six SCLC cell lines, the two CTC lines showed a significantly higher chemosensitivity to epirubicin (range, 3- to 16-fold) and topotecan (range, 2.2- to 14.4-fold), respectively.
conclusionsCTC cell lines derived from SCLC patients with recurrent disease exhibit high chemosensitivity to epirubicin vs. topotecan and show considerable more cytotoxicity in response to both compounds in comparison to a panel of SCLC cell lines. Thus, a decrease in the number of CTCs in response to second-line chemotherapy in SCLC patients may overestimate the effect on resident SCLC lesions and metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.